Liquid Biopsy Market to Hit $21.78 Billion by 2032 with 13.11% CAGR Growth

 

The Liquid Biopsy Market is on a strong upward trajectory, fueled by technological advancements, rising cancer prevalence, and the growing demand for non-invasive diagnostic solutions. According to the latest industry analysis, the Liquid Biopsy market size was valued at USD 7.20 billion in 2023 and is expected to surge to USD 21.78 billion by 2032, expanding at a robust compound annual growth rate (CAGR) of 13.11% from 2024 to 2032.

Get Free Sample Report on Liquid Biopsy Market

https://www.snsinsider.com/sample-request/5543

Liquid biopsy, a revolutionary technique that detects cancer biomarkers from blood or other bodily fluids, is transforming the way cancers are diagnosed, monitored, and managed. The increasing need for early detection, minimal invasiveness, and real-time monitoring of disease progression is driving widespread adoption across healthcare sectors worldwide.

Key Drivers Behind Market Growth

Several critical factors are propelling the growth of the Liquid Biopsy market:

  • Rising Cancer Incidence: With global cancer cases on the rise, there is an urgent demand for early, accurate, and less-invasive diagnostic techniques. Liquid biopsy provides a promising alternative to traditional tissue biopsies.
  • Technological Advancements: Breakthroughs in genomics, next-generation sequencing (NGS), and biomarker discovery have significantly improved the sensitivity and specificity of liquid biopsy tests.
  • Preference for Non-Invasive Procedures: Compared to conventional biopsies, liquid biopsy is less risky, less painful, and can be performed more frequently, making it a preferred choice for patients and physicians alike.
  • Growing Applications Beyond Oncology: Although cancer diagnostics dominate the market, liquid biopsy applications are expanding into areas like prenatal testing, transplant monitoring, and infectious disease management, further enhancing growth potential.
  • Personalized Medicine and Targeted Therapy: The ability of liquid biopsies to detect genetic mutations and guide targeted therapies is aligning perfectly with the global trend toward personalized medicine.

Key Market Segments:

By Product

  • Instruments
  • Consumables Kits and Reagents
  • Software and Services

By Technology

  • Multi-gene-parallel Analysis (NGS)
  • Single Gene Analysis (PCR Microarrays)

By Sample Type

  • Blood Sample
  • Others

By Biomarker

  • Circulating Tumor Cells (CTCs)
  • Circulating Nucleic Acids
  • Exosomes/ Microvesicles
  • Circulating Proteins

By Application

  • Cancer
  • Reproductive Health
  • Others

By Clinical Application

  • Therapy Selection
  • Treatment Monitoring
  • Early Cancer Screening
  • Recurrence Monitoring
  • Others

By End-use

  • Hospitals and Laboratories
  • Specialty Clinics
  • Academic and Research Centers
  • Others

 

Key Liquid Biopsy Comapnies

·         ANGLE plc – PARSORTIX

·         Oncimmune Holdings PLC – ImmunoINSIGHT

·         Guardant Health – Guardant360

·         Myriad Genetics, Inc. – myChoice CDx

·         Biocept, Inc. – Target Selector

·         Lucence Health Inc. – LiquidHALLMARK

·         Freenome Holdings, Inc. – Freenome Liquid Biopsy Platform

·         F. Hoffmann-La Roche Ltd. – Cobas EGFR Mutation Test v2

·         QIAGEN – QIAseq Targeted DNA Panels

·         Illumina, Inc. – NextSeq and MiSeq Systems

·         Thermo Fisher Scientific, Inc. – Oncomine Target Test

·         Epigenomics AG – Epi proColon

·         Natera, Inc. – Signatera

Future Outlook

The future of the Liquid Biopsy market appears highly promising. Advances in multi-cancer early detection (MCED) tests, liquid biopsy companion diagnostics, and personalized treatment monitoring are expected to revolutionize oncology practices over the next decade.

Make Enquiry about Liquid Biopsy Market        

https://www.snsinsider.com/enquiry/5543

Additionally, initiatives aimed at integrating artificial intelligence (AI) and machine learning (ML) into liquid biopsy analytics are likely to further enhance test accuracy, reduce turnaround time, and open new growth avenues.

Given its tremendous potential to redefine diagnostics and therapeutic monitoring, the Liquid Biopsy market is set to become a cornerstone of modern precision medicine, offering safer, faster, and more patient-friendly alternatives to traditional diagnostic approaches.

Conclusion

As the global healthcare industry moves toward less-invasive, patient-centric, and highly accurate diagnostic techniques, the Liquid Biopsy market is primed for extraordinary growth. With an expected market size of USD 21.78 billion by 2032, supported by a powerful CAGR of 13.11%, liquid biopsy is poised to play a transformative role in the future of disease management and personalized healthcare.

 About US

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Jagney Dave - Vice President of Client Engagement

Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

 

 

Comments

Post a Comment

Popular posts from this blog

Global Postpartum Care Market Forecast Shows 6.54% CAGR Growth Through 2032

  The Postpartum Products Market Size , valued at USD 2.53 billion in 2023 , is projected to reach USD 4.47 billion by 2032 , expanding at a CAGR of 6.54% over the forecast period from 2024 to 2032 , according to the latest industry research report. Postpartum products have become essential in modern maternity care, supporting new mothers in recovering from childbirth both physically and emotionally. These products—which include perineal care items, nursing accessories, postpartum garments, supplements, and more—play a vital role in enhancing comfort, hygiene, healing, and overall well-being during the postnatal period. Get Free Sample Report on Postpartum Products Market   https://www.snsinsider.com/sample-request/3361 Key Market Drivers 1. Increasing Global Birth Rate and Focus on Maternal Health Although some regions face declining birth rates, globally, over 140 million births occur annually , according to WHO. A significant portion of this population experien...
Read more

Platelet Rich Plasma Industry Booms: CAGR of 14.98% Forecasted Through 2032

  The global Platelet Rich Plasma (PRP) market Size is on a transformative growth trajectory, with the market size projected to rise from USD 0.75 billion in 2023 to USD 2.62 billion by 2032 , expanding at a Compound Annual Growth Rate (CAGR) of 14.98% during the forecast period of 2024–2032 . PRP therapy, known for its regenerative and healing properties, is gaining considerable traction in fields such as orthopedics, dermatology, sports medicine, and aesthetics . What is Platelet Rich Plasma (PRP)? Platelet Rich Plasma (PRP) is an autologous concentration of human platelets in a small volume of plasma. It has emerged as a promising treatment modality due to its rich content of growth factors , which play a pivotal role in tissue repair, regeneration, and inflammation modulation. PRP is prepared from a patient’s own blood and injected into the injured or targeted tissue to promote natural healing. Get Free Sample Report on Platelet Rich Plasma Market   http://snsins...
Read more